Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.5
4.8
Journals
Antibiotics
Special Issues
Next-Generation Interventions for Clostridioides difficile Infections to Minimize Microbiota Disturbance,...
share announcement

Next-Generation Interventions for Clostridioides difficile Infections to Minimize Microbiota Disturbance, Increase Efficacy, and Decrease Recurrence

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Genetic and Biochemical Studies of Antibiotic Activity and Resistance".

Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 6368

Special Issue Editors

Prof. Dr. Wen-Chien Ko

grade E-Mail Website
Guest Editor
Department of Medicine, National Cheng Kung University, Tainan, Taiwan
Interests: bacterial resistance; antibiotic treatment; bacterial infection; AIDS
Dr. Yuan-Pin Hung

E-Mail Website
Guest Editor
Department of Internal Medicine, Tainan Hospital, Ministry of Health and Welfare, Tainan, Taiwan
Interests: bacteremia; bloodstream infection; antimicrobial stewardship program; empirical; definitive; antibiotic
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Clostridioides difficile is the major cause of community- and healthcare-associated infections, ranging from mild diarrhea to pseudomembranous colitis or toxic megacolon. Among patients with C. difficile infection (CDI), oral vancomycin or fidaxomicin has been suggested for either mild–moderate or severe CDI. Nevertheless, oral anti-C. difficile antibiotics, such as vancomycin, markedly disrupt the intestinal microbiota and lead to prolonged loss of colonization resistance to CDI. Therefore, even with these therapeutic antibiotics, a high refractory or recurrent rate is noted among patients with CDI. Other therapeutic options for recurrent CDI are the introduction of competing nonpathogenic organisms (i.e., probiotics) or fecal microbiota transplantation to restore microbial balance.

Several new agents or administration regimens are aimed to preserve microbiota during CDI treatment to increase therapeutic efficacy or prevent disease recurrence; for this purpose, there are at least two therapeutic strategies: first, the development of narrow-spectrum antimicrobial agents; and second, the development of agents targeting distinct structures of C. difficile, such as anti-sense agents, anti-toxin antibodies, and agents targeting bacterial fatty acid synthesis. The anticipation of less disruption in microbiota will provide more chances to avoid CDI recurrence. Replenishing the disturbed microbiota may be another consideration of new drug development for CDI.

Therefore, we welcome the submission of interdisciplinary work and collaborative research. Original research articles, literature review, or meta-analyses that are relevant to treat CDIs are greatly encouraged.

Prof. Dr. Wen-Chien Ko
Dr. Yuanpin Hung
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Clostridioides difficile infection
  • Vancomycin
  • Fidaxomicin
  • Probiotics
  • Fecal microbiota transplantation
  • Microbiota
  • Metabolome
  • Recurrence

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

12 pages, 2529 KiB  
Article
Effect of Doxycycline in Decreasing the Severity of Clostridioides difficile Infection in Mice
by Bo-Yang Tsai, Yi-Hsin Lai, Chun-Wei Chiu, Chih-Yu Hsu, Yi-Hsuan Chen, Yueh-Lin Chen, Pei-Jane Tsai, Yuan-Pin Hung and Wen-Chien Ko
Antibiotics 2022, 11(1), 116; https://doi.org/10.3390/antibiotics11010116 - 17 Jan 2022
Viewed by 3651
Abstract
Background: Doxycycline possesses antibacterial activity against Clostridioides difficile and anti-inflammatory effects. Materials and Methods: The influence of doxycycline on the development of CDI was studied in an established animal model of CDI using C57BL/6 mice. Results: Mice intraperitoneally administered doxycycline had higher cecum [...] Read more.
Background: Doxycycline possesses antibacterial activity against Clostridioides difficile and anti-inflammatory effects. Materials and Methods: The influence of doxycycline on the development of CDI was studied in an established animal model of CDI using C57BL/6 mice. Results: Mice intraperitoneally administered doxycycline had higher cecum weight (1.3 ± 0.1 vs. 0.5 ± 0.1 g; p < 0.001) and less body weight reduction (0.7 ± 0.5 g vs. −17.4 ± 0.2 g; p < 0.001) than untreated mice infected with C. difficile. Oral doxycycline, metronidazole, or vancomycin therapy resulted in less body weight reduction in mice with CDI than in untreated mice (1.1 ± 0.1 g, 1.3 ± 0.2 g, 1.2 ± 0.1 g, vs. 2.9 ± 0.3 g; p < 0.001). Doxycycline therapy led to lower expression levels of inflammatory cytokines, such as macrophage inflammatory protein-2 (0.4 ± 0.1 vs. 2.9 ± 1.3, p = 0.02), and higher levels of zonula occludens-1 (1.2 ± 0.1 vs. 0.8 ± 0.1, p = 0.02) in colonic tissues than in untreated mice. Conclusions: Concurrent intraperitoneal administration of doxycycline and oral C. difficile challenge does not aggravate the disease severity of CDI, and oral doxycycline may be a potential therapeutic option for CDI. Full article
(This article belongs to the Special Issue Next-Generation Interventions for Clostridioides difficile Infections to Minimize Microbiota Disturbance, Increase Efficacy, and Decrease Recurrence)
►▼ Show Figures

Figure 1

Other

Jump to: Research

11 pages, 423 KiB  
Systematic Review
Fecal Microbiota Transplantation in Decompensated Cirrhosis: A Systematic Review on Safety and Efficacy
by Annie S. Hong, Kyaw Min Tun, Jenny M. Hong, Kavita Batra and Gordon Ohning
Antibiotics 2022, 11(7), 838; https://doi.org/10.3390/antibiotics11070838 - 23 Jun 2022
Cited by 7 | Viewed by 2239
Abstract
Background and Aims: Due to increasing knowledge of the “gut–liver axis”, there has been growing interest regarding the use of fecal microbiota transplant in the management of chronic liver disease. There are limited data available and current guidelines are mostly based on expert [...] Read more.
Background and Aims: Due to increasing knowledge of the “gut–liver axis”, there has been growing interest regarding the use of fecal microbiota transplant in the management of chronic liver disease. There are limited data available and current guidelines are mostly based on expert opinions. We aim to perform the first systematic review investigating safety and efficacy of fecal microbiota transplant particularly among high-risk decompensated cirrhosis patient populations. Methods: Literature search was performed using variations of the keywords “fecal microbiota transplant” and “cirrhosis” on PubMed/Medline from inception to 3 October 2021. The resulting 116 articles were independently screened by two authors. In total, 5 qualifying studies, including 2 randomized control trials and 3 retrospective case series, were found to meet established eligibility criteria and have adequate quality of evidence to be included in this review. Results: Of the total 58 qualifying patients, there were 2 deaths post fecal microbiota transplant, 1 of which could not rule out being related (1.7%). Among the remaining 56 participants, 8 serious adverse events were reported, of which 2 could not rule out being related (3.6%). The success rate of fecal microbiota transplantation in treating recurrent Clostridioides difficile infection among patients with decompensated cirrhosis was 77.8%. The success rate when used as investigational treatment for hepatic encephalopathy was 86.7%, with multiple studies reporting clinically significant improvement in encephalopathy testing scores. Conclusions: We found a marginally higher rate of deaths and serious adverse events from fecal microbiota transplant in our patient population compared with the average immunocompetent population, where it was previously found to have 0 deaths and SAE rate of 2.83%. The efficacy when used for recurrent C.difficile infection was 77.8% and 87% in the decompensated cirrhotic and general populations, respectively. Studies on efficacy in novel treatment of hepatic encephalopathy have been promising. This study concludes that fecal microbiota transplant use in decompensated cirrhosis patients should be used with caution and preferably be limited to research purposes until better data are available. Full article
(This article belongs to the Special Issue Next-Generation Interventions for Clostridioides difficile Infections to Minimize Microbiota Disturbance, Increase Efficacy, and Decrease Recurrence)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop